 FLORHAM PARK, N.J., May 11, 2021 GLOBE NEWSWIRE -- Phathom Pharmaceuticals, Inc. Nasdaq: PHAT, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2021 and provided an update on its recent clinical and organizational progress. 